Nectin 4 Expressing Advanced Malignancies clinical trials

Explore recruiting nectin 4 expressing advanced malignancies clinical trials.

Also recruiting in Europe

Nectin 4 Expressing Advanced Malignancies trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies.

Italy, France, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Nectin 4 Expressing Advanced Malignancies trials by city

Nectin 4 Expressing Advanced Malignancies in Toronto Nectin 4 Expressing Advanced Malignancies in Vancouver Nectin 4 Expressing Advanced Malignancies in Montreal Nectin 4 Expressing Advanced Malignancies in Calgary Nectin 4 Expressing Advanced Malignancies in Edmonton Nectin 4 Expressing Advanced Malignancies in Ottawa Nectin 4 Expressing Advanced Malignancies in Winnipeg Nectin 4 Expressing Advanced Malignancies in Quebec City Nectin 4 Expressing Advanced Malignancies in Hamilton Nectin 4 Expressing Advanced Malignancies in Kitchener Nectin 4 Expressing Advanced Malignancies in London Nectin 4 Expressing Advanced Malignancies in Halifax Nectin 4 Expressing Advanced Malignancies in New York Nectin 4 Expressing Advanced Malignancies in Los Angeles Nectin 4 Expressing Advanced Malignancies in Chicago Nectin 4 Expressing Advanced Malignancies in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease